The lowest sales estimate is $600,000.00 and the highest is $3.57 million. 06/01 08:49. Analyst Coverage. MT Newswires. The Optionality Value of the Emerging Pro-Drug Platform Is High: Ascendis is a pro-drug platform company that focuses on rare diseases related to endocrinology (hormones). Ascendis Pharma A/S (ASND Quick Quote ASND - Free Report) announced that the FDA has extended the review period of its biologics license … 05/28 13:00. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future … Ascendis Health Ltd is a drug manufacturer that produces and distributes health products for the human, animal, and plant markets. Analysts have been steadily raising their estimates for Ascendis Pharma A/S. We may contact a candidate via text to schedule an interview; however, that text will always be accompanied by a corresponding email from our Company's domains ( example@ascendispharma.com ). Analyst Price Target is. Ascendis Pharma A/S reported sales of $30,000.00 in the same quarter last year, which would suggest a positive […] Previous Next See Ascendis Pharma A/S Nav.-Akt. There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND – Research Report) and Esperion (ESPR – Research Report) with bullish sentiments.Ascendis Pharma (ASND) In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma, with a price target of $188.00. SVB Leerink reduced their price target on Ascendis Pharma A/S from $191.00 to $181.00 and set an "outperform" rating for the company in a report on Monday. $133.84. It's nice to see that Ascendis Pharma shareholders have gained 89% (in total) over the last year. Our investigational growth hormone prodrug releases somatropin (rhGH or hGH) with once-weekly administration. Ascendis Pharma A/S has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Credit Suisse analyst Alethia Young said she now believes Ascendis Pharma's (ASND) TransCon hGH can have dominant market share if its Phase 3 trial succeeds after Versartis' (VSAR) non-inferiority study testing somavaratan failed. +130.43% Upside Potential. 5 analysts offering 12-month price targets in the last 3 months for Ascendis Pharma evaluate the company at an average price target of $188.2 with a high of $201.00 and a … Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript. 2017 Avior investor lunch, Johannesburg 4.12.2017 Investor Remedica site visit 13/14th of November 2017 ASC Annual Results 2017 Presentation - RMB Off Piste Conference Sep17 Group Annual Results for year ended 30 June 2017 - Analyst Presentation Pre closing investor lunch Investec 12.6.2017 and Merrill Lynch 13.6.2017 Ascendis Health Interim Results 2017 - Analyst presentation … Review Your Overall Experience at Ascendis Pharma A/S. Description: Ascendis Pharma A/S is a biopharmaceutical company. Please note that any opinions, estimates or forecasts regarding Antares Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Antares Pharma… Ascendis Pharma A/S ... Analyst. Ascendis Pharma A/S (NASDAQ: ASND) stock closed at 130.36 per share at the end of the most recent trading day (a -0.35 % change compared to the prior day closing price) with a volume of 90.62K shares and market capitalization of 7.01B.Is a component of indices and it is traded on NASDAQ exchange. Ascendis Pharma A/S ADR balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Hey, guys, good afternoon. TransCon hGH, an investigational GHD therapy administered once weekly. Four analysts have issued estimates for Ascendis Pharma A/S’s earnings. A Different Perspective. Amount of Analyst Coverage. Analyst Ratings are available for US and Canadian equities. 2020 – nu 1 år 4 måneder. 9 February 2017 Ascendis Pharma A/S (ASND)3 Executive Summary We Are Initiating Coverage of Ascendis Pharma with an Outperform Rating and a $28 Target Price. Please note, that any opinions, estimates or forecasts regarding performance made by these analysts do not represent Fusion Pharmaceuticals or its management team.Fusion Pharmaceuticals is under no obligation to update this list, thus it may not be complete or up to date. Stifel Nicolaus assumed coverage on shares of Ascendis Pharma A/S in a report on Thursday, March 11th. How has Ascendis Pharma's share price performed over time and what events caused price changes? Ascendis Pharma A/S ADR analyst estimates, including ASND earnings per share estimates and analyst recommendations. Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Wednesday, May 26th. June 11, 2021. Please note that any opinions, estimates or forecasts regarding Antares Pharma, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Antares Pharma… Analyst Coverage. If the debt exceeds equity of ASCENDIS. Analyst Coverage. Ascendis Pharma A/S has a 52-week low of $119.11 and a 52-week high of $183.98. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. MT Newswires. A research report on Friday, 28th August said that the Credit Suisse Group raised the price target on Ascendis Pharma A/S (NASDAQ:ASND) from $154.00 to $158.00. Careers. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. The planned study is “extremely well powered for success”, it stated. Kit Zacho. Ascendis Pharma A/S ADR ASND ... are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst … MabVax Therapeutics (OTCMKTS:MBVXQ) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? SVB Leerink reduced their price target on Ascendis Pharma A/S from $191.00 to $181.00 and set an "outperform" rating for the company in a report on Monday. The group mainly focuses on supplying pharmaceutical products, animal health and medical devices. Zacks Investment Research cut shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a report released on Monday morning, Zacks.com reports. The business has a 50 day moving average of $135.21. Ascendis Health employees possess three core competencies: their dedication to succeed, entrepreneurial spirit and most importantly integrity. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. So we recommend checking out this free report showing consensus forecasts. Ascendis Pharma recent selloff a buying opportunity, says Canaccord 07/08/21-9:25AM EST Thefly.com Argus Research Initiates Equity Report Coverage on Ascendant Resources Inc. (TSX: ASND) The company’s shares closed last Friday at $127.24, close to its 52 … Ascendis Pharma is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Global Drug Delivery Market Forecasts to 2024 - Anticipated to Exceed $1 Trillion by 2024, with Pfizer, Insulet Corp, West Pharmaceutical Services, Enable Injections and Ascendis Pharma … Snippets. Achondroplasia Market Latest Trends and Forecast Analysis 2027 | Ascendis Pharma A/S, BioMarin, Ribomic, QED Therapeutics Posted by Harshad Borde March 1, 2021 Posted in Industry Insights To understand the market in depth, Achondroplasia Market research report is … 9 February 2017 Ascendis Pharma A/S (ASND)3 Executive Summary We Are Initiating Coverage of Ascendis Pharma with an Outperform Rating and a $28 Target Price. then the creditors have more stakes in a firm than the stockholders. This is an exciting opportunity to join a rapidly growing, innovative company! Antares Pharma, Inc. is followed by the analysts listed above. Since May 2020, Mr. Høiland has served as Senior Vice President and Global Chief Commercial Officer at Ascendis Pharma A/S. Brokerages forecast that Ascendis Pharma A/S (NASDAQ:ASND) will report $1.94 million in sales for the current quarter, Zacks Investment Research reports.
Itil Certification Udemy,
Used Truck Caps Massachusetts,
Prince George Celebrating England,
Asrock Z390 Taichi Manual,
Master Chief Collection M1 Mac,
Columbia Wall Paintings,
Armed Forces Covenant Jobs,
Different Ways To Get Eyebrows Done,